Evidence map›Paper›PMID 39607248›Full record

ArticleJournal of applied oral science : revista FOB2024

1,25(OH)2D3 increase osteogenic potential of human periodontal ligament cells with low osteoblast potential.

Bruno Cazotti Pereira, Catharina Marques Sacramento, Enilson Antonio Sallum, Mabelle de Freitas Monteiro, Renato Corrêa Viana Casarin, Marcio Zaffalon Casati, Karina Gonzales Silvério

Abstract readEvaluation Study
In one paragraph

Article in Journal of applied oral science : revista FOB, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bruno Cazotti PereiraUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0001-5800-6366
Catharina Marques SacramentoUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0003-2449-8168
Enilson Antonio SallumUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0003-3827-7091
Mabelle de Freitas MonteiroUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0001-9333-4349
Renato Corrêa Viana CasarinUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0003-1743-5855
Marcio Zaffalon CasatiUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0001-9234-0536
Karina Gonzales SilvérioUniversidade Estadual de Campinas - UNICAMP, Faculdade de Odontologia de Piracicaba, Piracicaba, SP, Brasil.ORCID http://orcid.org/0000-0001-5879-9095

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePeriodontal dental ligament mesenchymal stem cells (PDLMSCs) play a major role in periodontal tissue regeneration by the neoformation of root cementum and alveolar bone. These cells are highly heterogeneous, and many present low potential to renovate the hard tissue damaged by periodontal disease. A previous study found that the low osteoblast/cementoblast (O/C) differentiation potential of PDLMSCs is related to high asporin (ASPN) expression, which was identified as a negative regulator of PDL cells differentiation and mineralization, suppressing BMP-2-induced O/C differentiation. This study aimed to investigate whether 1,25(OH)2D3 treatment could stimulate the O/C differentiation of periodontal ligament mesenchymal progenitor cells characterized as low osteoblast potential (LOP), by asporin and bone morphogenetic protein-2 alteration. METHODOLOGY: Three LOP cell populations were cultured in standard medium (CONTROL), osteogenic medium (OM), and osteogenic medium associated with 1 nM of 1,25(OH)2D3 (OM + VD). The following assays were performed: 1) MTT to evaluate metabolic activity; 2) gene expression for asporin (ASPN), bone morphogenetic protein-2 (BMP-2), runt-related transcription factor 2 (RUNX2), alkaline phosphatase (ALP), osteocalcin (OCN), and vitamin D receptor (VDR) using qRT-PCR; 3) BMP-2 extracellular expression; and 4) quantification of mineralized nodule deposition by Alizarin Red Staining. Data were subjected to two-way ANOVA and Tukey's test (P<0.05).

resultsThe results showed that the 1,25(OH)2D3 treatment did not affect the cell viability, as demonstrated by metabolic activity increase over the 10 days in culture. After 14 days of 1,25(OH)2D3 treatment, the mRNA levels for ASPN and VDR decreased (P<0.05), while BMP-2 transcripts and extracellular expression increased (P<0.05). In parallel, RUNX2, ALP, and OCN gene expression was upregulated by 1,25(OH)2D3 treatment, resulting in an increase of mineral nodule deposition in vitro (P<0.05).

conclusionsThese data show that 1,25(OH)2D3 improves osteoblast/cementoblast differentiation of low osteoblast potential accompanied by alterations in ASPN and BMP-2 expression.

Indexed as

Bone Morphogenetic Protein 2Cell DifferentiationExtracellular Matrix ProteinsOsteoblastsOsteogenesisPeriodontal LigamentAlkaline PhosphataseAnalysis of VarianceCalcitriolCells, CulturedCore Binding Factor Alpha 1 SubunitGene ExpressionHumansMesenchymal Stem CellsOsteocalcinReal-Time Polymerase Chain ReactionAlkaline PhosphataseASPN protein, humanBMP2 protein, humanBone Morphogenetic Protein 2CalcitriolCore Binding Factor Alpha 1 SubunitExtracellular Matrix ProteinsOsteocalcinReceptors, Calcitriol

Identifiers

PMID39607248
PMCPMC11657088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.